NEW YORK, Nov. 6, 2017 /PRNewswire/ -- Artemis Therapeutics, Inc. (OTCQB: ATMS), ("Artemis" or the "Company"), a pharmaceutical company developing new therapies for the treatment of life-threatening infectious diseases, today
Growth Capitalist (https://growthcapitalist.com/2017/11/artemis-therapeutics-receives-orphan-drug-designation-from-u-s-food-and-drug-administration-for-artemisone-for-the-treatment-of-malaria/)
NEW YORK, Nov. 6, 2017 /PRNewswire/ -- Artemis Therapeutics, Inc. (OTCQB: ATMS), ("Artemis" or the "Company"), a pharmaceutical company developing new therapies for the treatment of life-threatening infectious diseases, today